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ABSTRACT
Local acidosis is a common feature of allergic, vascular, autoimmune, and cancer 
diseases. However, few studies have addressed the effect of extracellular pH on the 
immune response. Here, we analyzed whether low pH could modulate complement-
dependent cytotoxicity (CDC) against IgG-coated cells. Using human serum as a 
complement source, we found that extracellular pH values of 5.5 and 6.0 strongly 
inhibit CDC against either B lymphoblast cell lines coated with the chimeric anti-CD20 
mAb rituximab or PBMCs coated with the humanized anti-CD52 mAb alemtuzumab. 
Suppression of CDC by low pH was observed either in cells suspended in culture 
medium or in whole blood assays. Interestingly, not only CDC against IgG-coated 
cells, but also the activation of the complement system induced by the alternative and 
lectin pathways was prevented by low pH. Tumor-targeting mAbs represent one of the 
most successful tools for cancer therapy, however, the use of mAb monotherapy has 
only modest effects on solid tumors. Our present results suggest that severe acidosis, 
a hallmark of solid tumors, might impair complement-mediated tumor destruction 
directed by mAb.
INTRODUCTION
Low values of extracellular pH are usually found in 
tumors and inflamed tissues. Interstitial acidification (pH 
5.5–7.0) is associated with the course of inflammatory 
reactions against infectious agents in peripheral tissues [1–
6]. Autoimmune and allergic diseases are also associated 
with the development of acidic microenvironments. 
In fact, patients with rheumatoid arthritis show low pH 
values in the synovial fluid of compromised joints (6.5-
7.0), having the acidic pH being associated with synovial 
fluid leukocytosis and joint damage [7–9]. The lower 
airway of asthmatic patients also shows acidic values of 
extracellular pH during exacerbation of the disease. The 
pH of exhaled breath condensates from these patients is 
around 5.2, while healthy subjects showed values around 
7.2 [10, 11]. Local acidosis is a hallmark of tumor tissues. 
Values of extracellular pH ranging from 5.5 to 7.0 have 
been described in a number of solid tumors such as brain 
tumors, sarcomas, breast cancer, malignant melanoma, 
squamous cell carcinomas, and adenocarcinomas [12–16]. 
This acidic environment not only promotes local invasive 
growth and metastasis [17, 18], but also induces multi-
drug resistance due to the neutralization of weak base 
chemotherapeutic drugs [19].
Surprisingly, although it is widely appreciated that 
the immune response against pathogens, host antigens 
(autoimmunity) and tumor cells frequently occurs under 
acidic environments, not much is known about the 
influence of pH on the innate and the adaptive immune 
response. We have previously reported that low pH 
values induce the activation of neutrophils [20, 21] and 
conventional dendritic cells [22, 23], suggesting that local 
acidification could be recognized by immune cells as a 
danger-associated molecular pattern (DAMP), stimulating 
the immune response. These results were confirmed later 
in two independent studies [24, 25]. Monocyte, NK cell 
and T cell functions were also shown to be regulated by 
low pH values, in the range 6.0-7.2 [26–28]. Moreover, 
acidic environments have shown to delay the rate of 
apoptosis in neutrophils, endothelial cells and tumor cells 
[20, 29, 30].
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The constant fragment (Fc fragment) of IgG 
antibodies plays a crucial role in the induction of 
inflammatory and cytotoxic responses mediated by 
humoral and cellular components of the innate immune 
systems. The binding of IgG antibodies to their specific 
antigens can lead to the activation of the complement 
system, the induction of antibody-dependent cellular 
cytotoxicity (ADCC) and the phagocytosis of opsonized 
targets [31]. These mechanisms play an important role in 
antimicrobial immunity, autoimmunity, and host response 
against tumors [32, 33]. Moreover, they largely explain the 
therapeutic effects of mAbs used in cancer immunotherapy 
[34, 35]. The influence of low pH on the ability of IgG 
antibodies to induce complement-mediated cytotoxicity 
(CDC) has not yet been characterized. In this study, we 
show that pH values similar to those found in solid tumors 
inhibit CDC induced by IgG antibodies.
RESULTS
Low pH impairs complement-dependent 
cytotoxicity against IgG-coated target cells
In a first set of experiments, we determined the 
concentration of the anti-CD20 chimeric antibody rituximab 
(RTX) needed to destroy Raji cells by complement. Using 
10% HS as a complement source, we found that 2 μg/ml of 
RTX induces the necrosis of 60 to 75% of Raji cells after 
30 min of incubation, evaluated by PI staining and flow 
cytometry. A representative experiment is shown in Figure 
1A. Increasing the concentration of HS to 50% did not 
further increase cytotoxicity (Figure 1B), hence to analyze 
the effect of extracellular pH on cytotoxicity we used 2 μg/
ml of RTX to coat Raji cells and 10% HS as a complement 
source.
Figures 1C and 1D show that pH 5.5 almost 
completely prevented CDC against Raji cells, while pH 
6.0 reduced cytotoxicity by more than 50% compared 
with pH 7.3. No cytotoxicity was observed when HS 
was decomplemented by heating at 56°C for 30 min 
(Figure 1C). Similar results were observed using the B 
lymphocyte cell line Daudi instead of Raji cells (Figure 
1E) or when CDC assays were performed in Ca2+/Mg2+-
supplemented veronal-buffered saline instead of RPMI 
1640 medium (Figure 1F). The pH-dependence of CDC 
was also studied using an alternative approach to evaluate 
cell viability, a colorimetric method, instead of PI staining, 
based on the reduction of the tetrazolium compound [3-(4, 
5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium] to a formazan product by 
metabolically active cells. Consistent with the observations 
made by PI staining, we observed that low pH prevented 
Raji cell death evaluated by this alternative methodology 
(Figure 1G). Finally, to be sure that inhibition of CDC was 
not related to a diminished binding of RTX to Raji cells 
at low pH values, we analyzed the binding of RTX at pH 
7.3, 6.5, 6.0, and 5.5. Figure 1H shows that low pH did not 
inhibit the binding of RTX. In fact, a significant increase 
in the binding of RTX to Raji cells was observed at pH 
6.5, 6.0, and 5.5, compared to pH 7.3 (p<0.01, n=4).
To validate the observations made in B cell lines to 
other cell types, we analyzed the effect of pH on CDC 
against PBMCs coated with the humanized anti-CD52 
mAb alemtuzumab. All these experiments were performed 
using autologous serum. Preliminary experiments showed 
that 10 μg/ml of alemtuzumab saturated the PBMC’s 
binding capacity, evaluated by flow cytometry (data not 
shown). Figures 2A and 2B show that pH 5.5 almost 
completely impaired CDC, while pH 6.0 significantly 
prevented cytotoxicity. No cytotoxicity was observed 
when HS was decomplemented by heating at 56°C for 
30 min (Figure 2A). As expected, no inhibition in the 
binding of alemtuzumab to PBMCs was observed in the 
range of pH analyzed (Figure 2C). Together, our results 
suggest that severe acidosis (pH 5.5 and 6.0) prevents 
CDC irrespective of the nature of target cells.
Low pH impairs complement-dependent 
cytotoxicity against IgG-coated target cells 
mediated by both the classical and alternative 
pathways of activation
It is usually assumed that the destruction of IgG-
coated target cells by complement is mediated through 
the activation of the classical pathway. However, studies 
published by Taylor’s lab suggests a more complex 
picture, strongly dependent on the order in which the 
antibody and the complement source are added to target 
cells [36]. Working with B-cell lines treated with the anti-
CD20 mAbs RTX or ofatumumab, the authors reported 
that when B cells were first opsonized with antibodies in 
serum-free medium, washed, and then cultured with HS, 
CDC is mediated through the activation of the alternative 
pathway of complement. By contrast, when anti-CD20 
mAbs were added to B cells already suspended in HS, 
cytotoxicity is mainly mediated by the classical pathway 
of activation (36). Consistent with this unexpected 
observation, we found that when PBMCs were first 
opsonized with alemtuzumab in serum free medium, and 
then incubated with HS (10%), CDC was unaffected by 
the addition of Mg/EGTA, suggesting that cytotoxicity is 
mediated through the alternative pathway of activation. By 
contrast, when PBMCs were opsonized with alemtuzumab 
in the presence of HS (10%), CDC was strongly inhibited 
by Mg/EGTA, suggesting that cytotoxicity is mediated 
through the classical pathway of activation (Figure 3A). 
Interestingly, CDC assessed under both experimental 
conditions was similarly inhibited by low pH (Figures 3B 
and 3C), suggesting that acidosis prevents the activation of 
the alternative and classical complement pathways.
To further confirm that low pH inhibits both 
pathways, we analyzed the effect of pH on the ability 
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Figure 1: Low pH impairs CDC against RTX-coated B cell lines. A. Raji cells (5×105/100 μl) were treated with different 
concentrations of RTX (0.5 to 50 μg/ml) and incubated for 30 min at 37°C and pH 7.3, in RPMI medium supplemented with 10% of HS. 
Necrosis was then evaluated by propidium iodide staining and flow cytometry. A representative experiment (n=6) is shown. B. Raji cells 
(5 × 105/100 μl) were treated with 2 μg/ml of RTX and incubated in RPMI medium supplemented with different concentrations of HS 
(1 to 50%) for 30 min at 37°C and pH 7.3. Then, necrosis was evaluated. A representative experiment (n=8) is shown. C and D. Raji cells 
(5 × 105/100 μl) were treated with RTX (2 μg/ml) and then were incubated in RPMI medium supplemented with untreated (grey histograms) 
or heat-inactivated HS (open histograms) (10%) for 30 min at 37°C, at different values of pH. Then, necrosis was evaluated by propidium 
iodide staining and flow cytometry. Representative histograms and the mean ± SEM of 5 experiments performed in duplicate are shown 
(* p<0.05 vs pH 7.3 +Ab). E. Daudi cells (5 × 105/100 μl) were treated with RTX (2 μg/ml) and then were incubated in RPMI medium 
supplemented with HS (20%) for 30 min at 37°C at different values of pH. Then, necrosis was evaluated by propidium iodide staining 
and flow cytometry. Data represent the mean ± SEM of 4 experiments performed in duplicate (* p<0.05 vs pH 7.3 +Ab). F. Raji cells 
(5 × 105/100 μl) were treated with RTX (2 μg/ml) and then were incubated in Ca2+/Mg2+-veronal-buffered saline supplemented with 10% HS 
for 30 min at 37°C, at different values of pH. Then, necrosis was evaluated by propidium iodide staining and flow cytometry. Data represent 
the mean ± SEM of 4 experiments (* p<0.05 vs pH 7.3 +Ab). G. Raji cells (5 × 105/100 μl) were treated with RTX (2 μg/ml) and then were 
incubated in RPMI medium supplemented with heat-inactivated or untreated HS (10%) for 30 min at 37°C, at different pH values. Then, 
cells were suspended in colourless RPMI and cell viability was analyzed using a colorimetric commercial kit based on the ability of viable 
cells to reduce a tetrazolium compound to a formazan product, which was quantified by absorbance at 490 nm. Data represent the mean ± 
SEM of 4 experiments performed in duplicate (* p<0.05 vs pH 7.3). H. Raji cells (5 × 105/100 μl) were incubated at room temperature for 
30 min with RTX (2 μg/ml) in culture medium supplemented with 10% of heat-inactivated HS adjusted to different pH values. Then, cells 
were washed, and the binding of RTX to Raji cells was revealed using a FITC-labeled mAb directed to the Fc fragment of human IgG and 
flow cytometry. A representative experiment is shown (n=4).
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of HS to destroy either IgG-coated SRBC or rabbit red 
blood cells suspended in medium supplemented with 
Mg-EGTA, the two hemolytic systems commonly used 
to evaluate the classical and alternative pathways of 
complement activation, respectively [37, 38]. We found 
that pH 5.5 and 6.0 markedly inhibited CDC against IgG-
SRBC (Figure 3D). On the other hand, the lysis of rabbit 
red blood cells suspended in Mg-EGTA supplemented 
medium was shown to be significantly inhibited at pH 6.0 
and nearly completely abrogated at pH 5.5 (Figure 3E). 
We conclude that low pH inhibits CDC mediated by both, 
the classical and alternative pathways of complement 
activation.
Low pH impairs the generation of C3b, C4b and 
C3a induced by IgG-coated target cells
To further analyze the mechanisms underlying the 
ability of acidic pH to prevent CDC, we first determined 
whether the inhibition of cytotoxicity correlated with a 
reduced deposition of C3b on the surface of target cells. 
In these experiments, we used Raji cells (Figure 4A and 
4C) and PBMCs (Figure 4B and 4C) opsonized in serum 
free medium with RTX or alemtuzumab, respectively. 
Opsonized cells were incubated for 30 min at 37°C in the 
presence of 10% HS and the amount of C3b deposited on 
the cell surface was quantified by flow cytometry. Our 
results (Figure 4A-4C) show that low pH inhibited the 
generation/deposition of C3b on target cells. A similar 
inhibitory effect was observed when the deposition of 
C4b on alemtuzumab-coated PBMCs was examined 
(Figure 4D). Similar results were observed when PBMCs 
already suspended in 10% HS were opsonized with 
specific antibodies (data not shown).
We then looked at the effects of low pH on the 
production of C3a. In these experiments, autologous 
HS (20%) was incubated with or without (controls) 
alemtuzumab-coated PBMCs for 30 min, and the 
production of C3a was then evaluated by ELISA. 
The results obtained are showed in Figure 4E. As 
previously described, incubation of HS alone leads to 
the “spontaneous” activation of complement and the 
generation of low levels of C3a, perhaps reflecting 
the activation of the classical pathway induced by 
physiological concentrations of serum immune complexes 
[39]. Consistent with the ability of pH 6.5 to stimulate 
the alternative pathway of complement [40, 41], we 
found an enhanced generation of C3a at this pH value. 
By contrast, a significant reduction in the generation of 
C3a was observed when HS alone was incubated at pH 
6.0 or 5.5. Working with alemtuzumab-coated PBMCs, on 
the other hand, we found that the production of C3a was 
Figure 2: Low pH impairs CDC against alemtuzumab-coated PBMCs. A and B. PBMCs (5 × 105/100 μl) were treated with 
alemtuzumab (10 μg/ml) and then were incubated for 30 min at 37°C at distinct pH values in RPMI medium supplemented with 10% 
autologous HS. Necrosis was then evaluated by propidium iodide staining and flow cytometry. In (A), open histograms represent PBMCs 
treated with alemtuzumab (10 μg/ml) and incubated with 10% heat-inactivated autologous HS. Representative histograms (A) and the mean 
± SEM of 6 experiments performed in duplicate (B) are shown (* p<0.05 vs pH 7.3). C. PBMCs (5 × 105/100 μl) were incubated for 30 min 
at room temperature with alemtuzumab (10 μg/ml) in culture medium supplemented with 10% of heat-inactivated autologous HS adjusted 
to different values of pH. Then, cells were washed, and the binding of alemtuzumab to PBMCs was revealed using a FITC-labeled mAb 
directed to the Fc fragment of human IgG and flow cytometry. A representative experiment is shown (n=3).
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significantly inhibited at pH 6.0 and 5.5 compared with pH 
7.3. In fact, the ability of alemtuzumab-coated PBMCs to 
induce the production of C3a was completely abrogated at 
pH 5.5 (Figure 4E).
We then looked at the influence of low pH on the 
lectin pathway of complement activation. To this aim, HS 
(20%) was incubated on mannan-coated plates for 30 min 
at 37°C and the production of C3a was then evaluated 
by ELISA. Results in Figure 4F show that pH values of 
6.0 and 5.5 markedly prevented the enhancement in C3a 
generation induced by mannan. Low pH also strongly 
inhibited the deposition of the factor Bb and C3b on the 
surface of the fungi Candida albicans (Figure 5A), a 
strong inducer of the alternative pathway of complement 
[42], as well as the deposition of C3b and C9 on the 
surface of Salmonella enterica (Figure 5B). Overall, our 
observations suggest that the three major pathways of 
complement activation are inhibited by low pH and that 
this inhibition might compromise not only the anti-tumor 
activity mediated by therapeutic antibodies, but also the 
microbicidal action of the complement system.
Inhibition of CDC by low pH is a reversible 
phenomenon and occurs in whole blood
Then, we analyzed whether the inhibition of CDC by 
low pH could be overcome upon pH neutralization. This 
was tested in a new set of experiments using alemtuzumab-
coated PBMCs as target cells. Figures 6A and 6B show 
that abrogation of CDC by pH 5.5 was almost completely 
reversed upon pH neutralization, suggesting that inhibition 
of CDC by low pH is a reversible phenomenon. Finally, 
we addressed the question as to whether, in the more 
physiologic milieu of whole blood, low pH could also 
Figure 3: Low pH impairs CDC mediated by both the classical and alternative pathways of activation. A. Open bars: 
PBMCs (5 × 105/100 μl) were treated with alemtuzumab (10 μg/ml), washed and incubated for 30 min at 37°C and pH 7.3 with RPMI 
1640 medium supplemented with 10% HS, in the absence or presence of 5mM MgCl2 and 10 mM EGTA (EGTA/Mg). Black bars: PBMCs 
were suspended in RPMI 1640 medium supplemented with 10% HS (5 × 105/100 μl) and then were treated with alemtuzumab (10 μg/
ml). Cells were incubated for 30 min at 37°C and pH 7.3, in the absence or presence of EGTA/Mg. In all cases, necrosis was evaluated 
by propidium iodide staining and flow cytometry. Data represent the mean ± SEM of 4 experiments performed in duplicate. * p<0.05 vs 
PBMCs incubated with alemtuzumab in the absence of EGTA/Mg. B. PBMCs (5 × 105/100 μl) were treated with alemtuzumab (10 μg/
ml), washed and incubated for 30 min at 37° in RPMI 1640 medium supplemented with 10% HS, at different pH values. Necrosis was 
then evaluated by propidium iodide staining and flow cytometry. A representative experiment (n=4) is shown. C. PBMCs were suspended 
in RPMI 1640 medium supplemented with 10% HS (5 × 105/100 μl) and then were treated with alemtuzumab (10 μg/ml). Cells were 
incubated for 30 min at 37°C at different pH values, and necrosis was then evaluated by propidium iodide staining and flow cytometry. 
A representative experiment (n=5) is shown. D and E. Hemolytic assays of classical (D) and alternative (E) pathways of complement 
activation were performed at different values of pH as described under Materials and Methods. Data represent the mean ± SEM of 4-5 
experiments performed in triplicate. * p<0.05 vs pH 7.3.
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Figure 4: Low pH inhibits C3b, C4b and C3a generation. A-D. RTX-treated Raji cells (5 × 105/100 μl) and alemtuzumab-treated 
PBMCs (5 × 105/100 μl) were incubated in the presence of 10% HS or 10% autologous HS, respectively, for 30 min at 37°C, at different pH 
values. Then, the amount of C3b deposited on Raji cells (A and C) and PBMCs (B and C) as well as the amount of C4b deposited on Raji 
cells (D) was determined using a FITC-labeled mAb directed to C3b or C4b and flow cytometry. Representative histograms and the mean 
± SEM of 5-7 experiments are shown (* p<0.05 vs pH 7.3). E. HS (20%) was incubated in the absence or presence of alemtuzumab-treated 
PBMCs (5 × 105/100 μl), for 30 min at 37°C, at different pH values. Then, the concentration of C3a in the culture medium was determined 
by ELISA. Values represent the mean ± SEM of 4-5 experiments performed in duplicate (* p<0.05 vs pH 7.3). F. HS (20%) was incubated 
on uncoated or mannan-coated plates for 30 min at 37ªC, at different pH values. Then, the concentration of C3a in the culture medium was 
determined by ELISA. Values represent the mean ± SEM of 4 experiments performed in duplicate (* p<0.05 vs pH 7.3).
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inhibit CDC. Whole blood assays were performed as 
previously described [43]. Preliminary experiments showed 
that consistent with the weak expression of CD52 by 
neutrophils [44], they were not susceptible to CDC induced 
by alemtuzumab in whole blood assays. By contrast, both 
T and B lymphocytes were shown to be highly susceptible 
to CDC (not shown). To evaluate the ability of low pH to 
suppress CDC, aliquots of whole blood (100 μl) collected 
on either 3.2% sodium citrate (Figure 6C) or the thrombin 
inhibitor bivalirudin (50 μg/ml) (Figure 6D), were adjusted 
to different pH values and treated with alemtuzumab (50 
μg/ml) for 30 min at 37°C. Then, the absolute number of 
viable CD3+ T cells was determined by flow cytometry. 
In agreement with the observations made in isolated 
PBMCs, we found that low pH markedly inhibited T cell 
depletion in assays performed in whole blood collected in 
either sodium citrate or bivalirudin. In fact, T cell depletion 
mediated by complement was significantly inhibited at pH 
6.0 and almost completely prevented at pH 5.5 (Figures 
6C and 6D).
DISCUSSION
Using HS as a complement source, we here 
showed that severe acidosis (pH values of 5.5 and 6.0) 
inhibits CDC against IgG-coated target cells. Almost 
identical results were observed using B-cell lines and 
normal PBMCs, suggesting that low pH inhibits CDC 
irrespective of the nature of target cells. Abrogation of 
CDC by low pH appears to be a reversible phenomenon 
since it was completely reversed upon pH neutralization. 
Our observations also indicate that extracellular acidosis 
is able to inhibit the three major pathways of complement 
activation and that this inhibition might compromise 
not only the anti-tumor activity mediated by therapeutic 
antibodies, but also the microbicidal action of the 
complement system which also take place at inflammatory 
environments usually characterized by low values of 
extracellular pH [1–6]. Interestingly, inhibition of CDC 
was observed not only using cell lines and isolated 
PBMCs as target cells, but also in the more physiologic 
milieu of whole blood, suggesting that low pH might 
compromise the function of complement not only in vitro 
but also in vivo.
Previous reports have analyzed the influence 
exerted by acidic values of pH on the alternative and 
lectin pathways of complement activation. Studies 
performed with isolated complement components 
have shown that the optimal pH for the initiation and 
amplification of the alternative pathway of complement 
is 6.4, perhaps reflecting an increased generation of both 
C3 and C5 convertases [40, 41, 45]. Acidic values of 
Figure 5: Low pH prevents C3b, factor Bb and C9 deposition on Candida albicans or Salmonella enterica. A. Candida 
albicans (5 × 105/200 μl) was incubated for 30 min in RPMI medium supplemented with untreated (open histograms) or heat-inactivated 
(filled histograms) HS (10%), adjusted to different pH values. Yeasts were then washed and the deposition of C3b and factor Bb was analyzed 
by flow cytometry or fluorescence microscopy. B. Salmonella enterica serovar Enteritidis was incubated for 30 min at 5 × 106/200 μl in 
RPMI medium supplemented with untreated (open histograms) or heat-inactivated (filled histograms) HS (10%), adjusted to different pH 
values. Then C3b and C9 deposition on the bacterial surface was revealed by flow cytometry. Representative histograms or images from 
4-7 experiments are shown.
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pH have also shown to modulate the ability of the acute 
phase reactant C-reactive protein (CRP) to activate the 
complement system. It is well known that CRP activates 
the classical pathway of complement upon reaction with 
phosphocholine-containing or polycation-containing 
ligands, and it has been shown that mildly acidic 
conditions (optimal pH ~ 6.3) enables CRP to effectively 
activate complement even in the absence of these ligands 
[46]. Moreover, Zhang and coworkers [47] have reported 
that mild acidosis (pH 6.5) favors the interaction of CRP 
with a second acute phase reactant, L-ficolin, leading to an 
enhanced deposition of C3 on the bacterial surface, and an 
increased bactericidal activity of human serum.
C1q is the key molecule required for the initiation 
of the classical pathway of complement activation. It 
interacts with the Cγ2 domain of IgG or the Cμ3 domain 
of IgM when these antibodies have recognized antigens, 
leading to the formation of immune complexes [48]. 
Previous studies have analyzed the influence exerted 
by low pH on the recognition of IgG by C1q, however, 
contrasting results have been reported. Using immobilized 
human IgG as an immune complex model, Kaul and 
Loos [49] have reported that the recognition of IgG by 
C1q is lower at pH 6.5, 6.0, and 5.5, compared with pH 
7.4. By contrast, using heat-aggregated human IgG1, 
Roumenina and coworkers [50] demonstrated that the 
recognition of IgG by C1q shows an optimal pH of 5.5, 
and markedly decreases at neutral values of pH. These 
contrasting results suggest that the effect exerted by pH 
on the activation of the classical pathway of complement 
Figure 6: Inhibition of CDC by low pH occurs in whole blood and is a reversible phenomenon. A and B. Alemtuzumab-
treated PBMCs (5 × 105/100 μl) were incubated for 30 min at 37°C with 10% autologous HS, at pH 5.5. Then, the pH was adjusted to pH 
7.3 (grey histograms) or remained at pH 5.5 (black line), and cells were further incubated for a period of 30 min at 37°C. Finally, necrosis 
was evaluated by PI staining and flow cytometry. Controls represent alemtuzumab-treated PBMCs incubated for 60 min at 37°C and pH 7.3 
in the presence of 10% autologous HS (dotted lines). Representative histograms or the mean ± SEM of 5 experiments are showed (*p<0.05 
vs pH 7.3). C and D. Aliquots of peripheral blood (100 μl) collected on 3.2% sodium citrate (C) or bivalirudin (50μg/ml) (D) were adjusted 
to different pH values and treated with alemtuzumab (50 μg/ml). After 30 min incubation at 37°C, cells were stained with FITC-conjugated 
anti-CD3 mAb and PerCP-7AAD. The percentage of CD3+/7AAD- cells was determined for each condition and the results were expressed 
as the percentage of T cell depletion compared with untreated blood samples. Controls were made by incubating aliquots of peripheral 
blood, adjusted to different pH values, without alemtuzumab. Data represent the mean ± SEM of 4-5 experiments. *p<0.05 vs pH 7.3.
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might be strongly influenced by the characteristics of the 
triggering stimulus. Not only the effector pathways of 
complement activation are susceptible to be modulated 
by pH in the range comprised between 5.0 and 7.5, but 
also natural complement inhibitors have shown to act in a 
pH-dependent manner. The ability of CR1 to promote the 
cleavage of C3b by factor I shows an optimum pH of 7.5 
and decreases at pH values of 6.0 and 5.0. By contrast, the 
activity of factor H has been shown to be markedly higher 
at pH 5.0 compared to pH 7.5 [51] while the binding of 
factor I to either C3b or factor H reaches a maximum at 
pH 4.0 to 5.5, showing a sharp decrease at neutral pH 
values [52]. An enhanced ability of factor H to promote 
the cleavage of C3b by factor I might contribute to the 
inhibition of CDC by low pH observed in the present 
study.
The mechanism by which low pH impairs CDC 
is yet to be defined. The complement proteins C3 and 
C4 have an internal thioester which becomes available 
to react with amino or hydroxyl groups on the target 
surface upon activation [53]. This step plays a critical 
role in complement activation and appears to be strongly 
dependent on the presence of a single histidine residue 
(either in C3 or C4) which acts as a base or a nucleophile 
to attack the internal thioester, leading to the interaction of 
C3b and C4b with the target cell surface [54, 55]. Because 
the imidazole side chain of histidine has a pKa of 6.0, we 
hypothesize that protonation of this histidine residue at pH 
values of 6.0 and 5.5 might impair its ability to attack the 
internal thioester, thus preventing both, the binding of C3b 
and C4b to the target cell surface and the assembly of C3 
convertases. Further experiments are needed to test this 
hypothesis.
Strikingly, no previous studies have investigated 
the influence exerted by extracellular pH on the lysis 
of IgG-coated cells by complement. Because the 
recognized ability of IgG-coated cells to activate the 
classical complement pathway, it has been assumed 
that the formation of the membrane attack complex 
(MAC) is mainly induced through the activation of 
the classical pathway and that the alternative pathway 
merely acts as a positive feedback amplification loop. 
This assumption is also consistent with the traditional 
view according to which the activation of the alternative 
pathway is considered to be antibody-independent. 
However, a number of studies have clearly shown that 
immune complexes can activate the alternative pathway 
of complement [56]. In line with these reports, and in 
agreement with previous observations made by Beum 
and coworkers in B cell lines opsonized with anti-CD20 
antibodies [36], we found that the activation pathway 
responsible for CDC against alemtuzumab-opsonized 
PBMCs depends on the experimental conditions under 
which the assay is performed. When PBMCs were first 
opsonized with alemtuzumab in serum-free medium and 
then incubated with HS, CDC was shown to be unaffected 
by EGTA/Mg, suggesting that cytotoxicity is mediated 
through the activation of the alternative pathway. By 
contrast, when alemtuzumab was added to PBMCs already 
suspended in HS, CDC was abrogated by EGTA/Mg, 
suggesting the involvement of the classical pathway. The 
reasons underlying these differences are unclear, however, 
we found that pH values of 6.0 and 5.5 inhibited CDC 
assessed in both experimental conditions, reflecting the 
ability of severe acidosis to prevent the activation of the 
alternative and classical pathways of complement.
Cancer therapy based on the use of mAb is one 
of the most successful approaches for the treatment of 
patients with hematological malignancies and some solid 
tumors [57]. Mechanisms contributing to mAb-induced 
tumor cell death include CDC, antibody-dependent 
cellular cytotoxicity (ADCC), and induction of apoptosis 
by direct transmembrane signaling [57, 58]. A large body 
of evidence suggests that CDC plays an important role in 
the therapeutic activity of some mAb [59]. C1q deficient 
mice show a poor response to mAb-based therapies 
[60]. Patients with chronic lymphocytic leukemia suffer 
acute complement depletion upon administration of 
RTX, indicating an effective activation of complement 
in vivo [61]. Moreover, polymorphisms in complement 
components and complement regulatory factors have 
shown to be associated to the efficacy of immunotherapy 
[62, 63].
Our present results suggest that low values of 
extracellular pH, similar to those found in solid tumors 
[12–16], might represent an important obstacle for 
mAb-based therapies because CDC would be impaired. 
Importantly, not only CDC, but also ADCC mediated by 
NK cells against IgG-coated tumor cells appears to be 
strongly inhibited by low pH [26, 64], emphasizing that 
acidic microenvironments might limit the effectiveness 
of therapeutic mAb. This raises the question whether 
anti-tumor mAb could be combined with agents capable 
of raising tumor extracellular pH in order to improve 
the therapeutic effect. Interestingly, considering that 
acidic environments not only promotes tumor invasive 
growth and metastasis [17, 18], but also induces multi-
drug resistance due to the neutralization of weak base 
chemotherapeutic drugs [19], it has been suggested 
that manipulation of the extracellular pH might have 
considerable potential as cancer therapy [65]. In fact, 
preclinical studies have shown that proton pump inhibitors 
increase tumor extracellular pH and exert anti-tumor 
effects [66–67]. Interestingly, not only proton pump 
inhibitors but also mTOR inhibitors such as rapamycin or 
rapamycin analogues (rapalogs), used in the treatment of 
cancer [68, 69] have shown to decrease lactate production 
by tumor cells increasing extracellular pH [70]. Whether 
raising tumor extracellular pH by either proton pump 
inhibitors or rapamycin could improve the efficacy 





Peripheral blood mononuclear cells (PBMCs) 
were isolated from heparinized human blood samples 
by standard density gradient centrifugation on Ficoll-
Hypaque, and resuspended in RPMI 1640 medium 
(Invitrogen Life Technologies) supplemented with the 
indicated concentration of autologous serum. The B cell 
lines Raji and Daudi were obtained from the American 
Type Culture Collection and cultured in RPMI 1640 
medium supplemented with 10% heat-inactivated fetal 
calf serum, 50 U/ml penicillin, 50 μg/ml streptomycin, 
and 0.1 mM nonessential amino acids (Invitrogen Life 
Technologies).
Culture conditions
Extracellular acidification was achieved by 
the addition of a precalculated volume of isotonic 
hydrogen chloride solution to either, the culture medium 
supplemented with HS or whole blood samples, as we 
had previously described [20]. In all cases, cell cultures 
were maintained at 37°C in a humidified atmosphere 
supplemented with 5% CO2, and the pH was checked by 
using a pH meter (Jensen Instrument Co).
Complement-dependent cytotoxicity (CDC)
Unless otherwise stated, CDC assays were 
performed as follows. The B lymphoblast cell lines 
Raji and Daudi, and human PBMCs were treated with 
the indicated concentrations of the chimeric anti-CD20 
mAb rituximab (RTX) or the humanized anti-CD52 mAb 
alemtuzumab, respectively. Then, cells (5 × 105/100 μl) 
were incubated in RPMI 1640 medium supplemented with 
10% human serum (HS), used as a complement source. 
Autologous HS was used in the assays performed with 
PBMCs. After 30 min of incubation at 37°C and different 
pH values, the percentage of necrotic cells was determined 
by propidium iodide (PI) staining and flow cytometry on 
a FACSCanto II instrument (BD Biosciences). In some 
experiments, CDC was assessed using cells suspended in 
Ca2+/Mg2+-supplemented veronal-buffered saline instead 
of RPMI medium. Moreover, CDC was also assessed 
using a colorimetric method to determine cell viability, 
instead of PI staining, based on the ability of metabolically 
active cells to reduce the tetrazolium compound [3-(4, 
5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium] to a formazan product 
(CellTiter 96 aqueous one solution cell proliferation assay 
kit, Promega).
In all cases, inactivation of HS was induced by 
heating at 56°C for 30 min. When indicated the CDC 
assay was performed as follows: PBMCs were first 
suspended in RPMI 1640 medium supplemented with 10% 
HS (5 × 105/100 μl), and the anti-CD52 mAb alemtuzumab 
was then added, in the absence or presence of MgCl2 (5mM) 
and EGTA (10 mM) (Mg-EGTA). Cells were incubated for 
30 min at 37°C at different pH values and the percentage 
of necrotic cells was determined by propidium iodide 
(PI) staining and flow cytometry. To analyze whether the 
inhibitory effect induced by low pH on CDC was reversible, 
alemtuzumab-coated target cells (5 × 105/100 μl) were first 
incubated with RPMI 1640 medium supplemented with 
10% HS for 30 min at pH 5.5. Then, the pH of the culture 
medium was neutralized by the addition of isotonic NaOH, 
and cells were further incubated for 30 min at pH 7.3. 
After this time, necrosis was evaluated as described above. 
Controls were carried out by incubating alemtuzumab-
coated target cells for 60 min at pH 7.3 or 5.5.
Hemolytic assays of classical and alternative 
pathways of complement activation
Assays were performed as previously described with 
minor modifications [37, 38]. Briefly, hemolytic assay 
for evaluation of the classical pathway of complement 
activation was performed using 5 × 107 sheep red blood 
cells (SRBC) opsonized with rabbit IgG antibodies anti-
SRBC (Sigma-Aldrich). Cells were suspended in RPMI 
1640 medium without phenol red supplemented with 10% 
HS and adjusted to different pH values, in a final volume 
of 100 μl. Cells were then incubated for 30 min at 37°C. 
Then, cells were centrifuged and hemolysis was evaluated 
by measuring OD at 540 nm. Blanks were prepared with 
5 × 107 SRBC opsonized with rabbit IgG antibodies anti-
SRBC, suspended in RPMI 1640 medium without phenol 
red supplemented with 10% heat-inactivated HS and 
adjusted to different pH values, in a final volume of 100 μl. 
The OD of 5 × 107 SRBC lysed by the addition of 100 μl 
of distilled water was taken as 100% lysis. In all cases, the 
absorbance of blank tubes was lower than 10% compared 
with the absorbance of the tubes with 100% lysis. The 
percentage of lysis for each experimental condition was 
calculated as follows: [OD540 (X) – OD540 (blank)] / [OD540 
(100%) – OD540 (blank)] / x 100. The hemolytic assay 
for evaluation of the alternative pathway of complement 
activation was performed using 2.5 × 107 rabbit red blood 
cells suspended in RPMI 1640 medium without phenol 
red supplemented with 20% HS, 5mM MgCl2 and 10 mM 
EGTA (Mg/EGTA) adjusted to different pH values, in a 
final volume of 100 μl. Cells were incubated for 30 min at 
37°C, centrifuged, and hemolysis was then evaluated by 
measuring OD at 540 nm. The percentage of lysis for each 
experimental condition was calculated as described above.
Analysis of C3b and C4b deposition on the 
surface of IgG-coated target cells
Raji cells and PBMCs were treated with the anti-
CD20 mAb RTX (2μg/ml) or the anti-CD52 mAb 
alemtuzumab (10 μg/ml), respectively, for 15 min at 37°C. 
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Then, cells (5 × 105/100 μl) were incubated for 30 min at 
37°C in RPMI 1640 medium supplemented with 10% of 
HS, at different values of pH. After washing, C3b and/or 
C4b deposition on the cell surface was revealed by flow 
cytometry using specific FITC-labeled mAbs (AssayPro).
Analysis of C3b, factor Bb, and C9 deposition 
on the surface of Candida albicans or Salmonella 
enterica
Candida albicans (ATCC10231) was incubated for 
30 min at a density of 5 × 105/200 μl in RPMI medium 
supplemented with 10% HS, adjusted to different pH 
values. After washing, C3b and factor Bb deposition 
on the yeast surface was revealed by flow cytometry 
using specific FITC- or APC-labeled mAbs (AssayPro). 
Salmonella enterica serovar Enteritidis (#5694) was 
incubated for 30 min at a density of 5 × 106/200 μl in 
RPMI supplemented with 10% HS, adjusted to different 
pH values. After washing, C3b and C9 deposition on the 
bacterial surface was revealed by flow cytometry using 
specific FITC- or APC-labeled mAbs (AssayPro).
Analysis of C3a generation induced by IgG-
coated cells and mannan-coated plates
HS (20% in RPMI 1640 medium) was incubated for 
30 min at 37°C with or without PBMCs (5 × 105/100 μl), 
previously treated with the anti-CD52 mAb alemtuzumab 
(10 μg/ml). Then, the presence of C3a in the culture 
medium was analyzed by ELISA (Quidel).
To analyze the influence of low pH on the lectin 
pathway of complement activation we used mannan-
coated plates, as previously described [71]. Briefly, HS 
(20%) was incubated for 30 min at 37°C in 96 well Nunc 
Maxisorb microtiter plates, uncoated or coated with 10 μg/
ml of mannan (Sigma-Aldrich). Then, the production of 
C3a was analyzed by ELISA.
Measurement of complement-dependent 
cytotoxicity in whole blood
It was performed as previously described [42]. 
Unmanipulated peripheral blood of healthy donors 
collected on either 3.2% sodium citrate or the specific 
thrombin inhibitor bivalirudin (Amuprux, Lab. Raffo, 
Argentina) (50μg/ml), were adjusted to different pH values 
and treated with alemtuzumab, to a final concentration 
of 50 μg/ml. Whole blood samples were incubated for 
30 min at 37°C, and then stained for 15 min at room 
temperature with FITC-conjugated anti-CD3 mAb and 
PerCP-7AAD (BD Biosciences). Samples were then lysed 
with a whole blood lysing solution (BD Biosciences) to 
eliminate red blood cells and analyzed by flow cytometry. 
The percentage of CD3+/7AAD- cells was evaluated for 
each condition and the results were expressed as the 
percentage of T cell depletion compared with untreated 
blood samples. Controls were made by incubating aliquots 
of peripheral blood adjusted to different pH values without 
alemtuzumab.
Statistical analysis
Student’s paired t test was used to determine the 
significance of differences between mean values, and 
p<0.05 was determined to indicate statistical significance.
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